BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2528 related articles for article (PubMed ID: 26587983)

  • 1. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
    Marik PE; Cavallazzi R
    PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
    Robertson L; Yeoh SE; Ramli A
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair.
    Forster R; Stewart M
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD004179. PubMed ID: 27027384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
    Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
    Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
    Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis.
    Mai V; Bertoletti L; Cucherat M; Jardel S; Grange C; Provencher S; Lega JC
    PLoS One; 2019; 14(4):e0214134. PubMed ID: 30933993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation.
    Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Barba M; Yosuico VED; Terrenato I; Sperati F; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD006466. PubMed ID: 29285754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which patients with unprovoked venous thromboembolism should receive extended anticoagulation with direct oral anticoagulants? A systematic review, network meta-analysis, and decision analysis.
    Djulbegovic M; Lee AI; Chen K
    J Eval Clin Pract; 2020 Feb; 26(1):7-17. PubMed ID: 31190408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis.
    Khan F; Tritschler T; Kimpton M; Wells PS; Kearon C; Weitz JI; Büller HR; Raskob GE; Ageno W; Couturaud F; Prandoni P; Palareti G; Legnani C; Kyrle PA; Eichinger S; Eischer L; Becattini C; Agnelli G; Vedovati MC; Geersing GJ; Takada T; Cosmi B; Aujesky D; Marconi L; Palla A; Siragusa S; Bradbury CA; Parpia S; Mallick R; Lensing AWA; Gebel M; Grosso MA; Thavorn K; Hutton B; Le Gal G; Fergusson DA; Rodger MA;
    Ann Intern Med; 2021 Oct; 174(10):1420-1429. PubMed ID: 34516270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis.
    Wang X; Ma Y; Hui X; Li M; Li J; Tian J; Wang Q; Yan P; Li J; Xie P; Yang K; Yao L
    Cochrane Database Syst Rev; 2023 Apr; 4(4):CD010956. PubMed ID: 37058421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review.
    Wu C; Alotaibi GS; Alsaleh K; Sean McMurtry M
    Thromb Res; 2014 Sep; 134(3):627-32. PubMed ID: 25047174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
    Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012169. PubMed ID: 33045766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review.
    Gómez-Outes A; Lecumberri R; Suárez-Gea ML; Terleira-Fernández AI; Monreal M; Vargas-Castrillón E
    J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):490-500. PubMed ID: 25802423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of distal deep vein thrombosis.
    Kirkilesis G; Kakkos SK; Bicknell C; Salim S; Kakavia K
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD013422. PubMed ID: 32271939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic therapy for secondary prevention of unprovoked venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials.
    Li D; Liu Y; Song Y; Wen A
    Ann Med; 2022 Dec; 54(1):253-261. PubMed ID: 35023788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents.
    Kahale LA; Matar CF; Tsolakian I; Hakoum MB; Yosuico VE; Terrenato I; Sperati F; Barba M; Hicks LK; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD014739. PubMed ID: 34582035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register.
    Palareti G; Legnani C; Antonucci E; Cosmi B; Falanga A; Poli D; Mastroiacovo D; Pengo V; Ageno W; Testa S
    Ther Adv Drug Saf; 2021; 12():20420986211062965. PubMed ID: 34987749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
    Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism.
    Li M; Li J; Wang X; Hui X; Wang Q; Xie S; Yan P; Tian J; Li J; Xie P; Yang K; Yao L
    Cochrane Database Syst Rev; 2023 Apr; 4(4):CD010957. PubMed ID: 37057837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 127.